BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
AJOVY (fremanezumab-vfrm) by Teva is fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (cgrp) ligand and blocks its binding to the receptor. First approved in 2018.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AJOVY (fremanezumab-vfrm) is a humanized monoclonal antibody that blocks calcitonin gene-related peptide (CGRP) ligand, preventing its binding to the receptor. It is administered via subcutaneous injection for migraine prevention. The drug represents a novel mechanism class for reducing migraine frequency in patients with episodic or chronic migraine.
Peak
At peak lifecycle stage with moderate competitive pressure (30/100), the brand likely maintains a stable mid-sized commercial team focused on maintaining market share and managed care access.
Mechanism of Action
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Started Apr 2022
1,000 enrolled
Migraine Disorders
Career Relevance
Working on AJOVY positions you in a mature, competitive migraine market where success depends on managed care negotiations, patient education, and defending market share against CGRP competitors. The brand offers exposure to biologic commercialization and specialty care dynamics in a high-prevalence indication, though limited open positions suggest a stabilized team size.
Brand Manager
Worked on AJOVY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.